Lantheus Holdings, Inc.
201 Burlington Road
South Building
Bedford, MA 01730
United States
978 671 8001
https://www.lantheus.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 834
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Brian A. Markison | CEO & Director | 139.19k | 無 | 1959 |
| Mr. Paul M. Blanchfield | President | 1.18M | 無 | 1982 |
| Mr. Robert J. Marshall Jr., CFA | CFO & Treasurer | 1.3M | 無 | 1967 |
| Mr. Daniel M. Niedzwiecki | Chief Administrative Officer, General Counsel & Corporate Secretary | 920.09k | 133.82k | 1978 |
| Dr. Jean-Claude Provost M.D. | Chief Medical Officer | 901.8k | 無 | 無 |
| Ms. Andrea Sabens | Chief Accounting Officer | 無 | 無 | 1979 |
| Ms. Dorothy Barr | Senior Vice President of Manufacturing & Technical Operations | 無 | 無 | 無 |
| Mr. Mark Richard Kinarney | Senior Director of Investor Relations | 無 | 無 | 無 |
| Ms. Linda S. Lennox | VP of Corporate Communications & Chief of Staff | 無 | 無 | 1966 |
| Ms. Carol Walker | Senior Vice President of Quality | 無 | 無 | 1963 |
描述
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
公司管治
截至 2024年4月29日 止，Lantheus Holdings, Inc. 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：5；董事會：5；股東權利：2；現金賠償：2。
